240 likes | 425 Views
Training of clinical trial specialists and reviewers: Current situation of Pharmaceutical Medicine Kihito Takahashi President of JAPhMed. The 6th Kitasato University-Harvard School of Public Health Symposium Tuesday, October 26th, 2005. Today’s Agenda. JAPhMed and IFAPP
E N D
Training of clinical trial specialists and reviewers: Current situation of Pharmaceutical Medicine Kihito Takahashi President of JAPhMed The 6th Kitasato University-Harvard School of Public Health SymposiumTuesday, October 26th, 2005
Today’s Agenda • JAPhMed and IFAPP • Pharmaceutical Medicine: Current Global Situation • Path Forward for Training and Education in Japan
Japanese Association of Pharmaceutical Medicine (JAPhMed) • JAPhMed is a group of physicians, mostly working in the pharmaceutical industry, with the following goals: • To contribute to the advancement of the pharmaceutical industry • To provide opinions on evaluation of efficacy and safety of pharmaceuticals from medical point of view • To develop understanding about the role and importance of medical doctors in pharmaceutical companies • To foster international exchange for the above-mentioned purposes • To promote Pharmaceutical Medicine in Japan
IFAPP: The International Federation of Associations of Pharmaceutical Physicians • The International Federation of Associations of Pharmaceutical Physicians (IFAPP) was founded in 1975 to promote international cooperation among medical doctors working in pharmaceutical companies around the world • Japan, through JAMDI (the predecessor of JAPhMed), was one of original member countries in the foundation of IFAPP • IFAPP also has a primary objective to establish the role of Pharmaceutical Medicine and pharmaceutical physicians on a global basis
What is Pharmaceutical Medicine? • Definition of Pharmaceutical Medicine • Pharmaceutical Medicine is a medical scientific specialty concerned with the discovery, development, evaluation, registration, monitoring and medical aspects of marketing of medicines for the benefit of patients and the public health • Faculty of Pharmaceutical Medicine, Royal College of Physicians (RCP) • Careers in pharmaceutical medicine encompass three main groups of physicians and qualified non-physicians: • Those working in the pharmaceutical industry • Those with appointments within medicines regulatory bodies • Those working in independent research organizations dedicated to the development of new medicines (e.g. academia, CRO)
Pharmaceutical Medicine in Europe • In Britain, the British Association of Pharmaceutical Physicians (BrAPP) introduced a 2-year program of part-time study in 1975 • The Royal College of Physicians (RCP) has been supporting this initiative by providing examinations for a diploma in Pharmaceutical Medicine based on the BrAPP syllabus • Similar accreditation systems have been adopted in other countries: • Switzerland • Belgium • Germany • France • Italy • Sweden • Spain • Argentina (South America)
European Center of Pharmaceutical Medicine - Example • European Center of Pharmaceutical Medicine (ECPM) is a university institute within the Medical Faculty of the University of Basel • Course: • A postgraduate education program especially designed for professionals working within the pharmaceutical industry, regulatory authorities and university hospitals • Established in 1991, providing specialist knowledge in the field of drug development at an advanced level. • Emphasis is placed on requirements for rational and rapid development of a new drug for the world market • Eligibility Criteria: • Applicants must have a university degree, MD or PhD • The program is aimed at scientists who are involved in the drug development process and have already at least 1 to 2 years of working experience • Diploma: • Participants who successfully complete the course cycle and pass the final (multiple-choice) examination will be awarded a diploma by the three EUCOR medical schools:University of Basel, Albert-Ludwigs University, and Louis Pasteur University • Examinations: • A multiple-choice questionnaire for self assessment of acquired knowledge
A majority of Pharmaceutical Medicine Courses accept both physicians and non-physicians • Except for two universities, most of Pharmaceutical Medicine Courses in Europe accept both physicians and non-physicians: Student Ratio Physicians to non-Physicians in each course in Europe Non-Physicians Physicians Source: HP of each school
Pharmaceutical Medicine in the United States • The American Academy of Pharmaceutical Physicians (AAPP) has been chartered since 1994 with the mission to contribute toward the progress and advancement of Pharmaceutical Medicine • The largest single group of physicians in this specialty • Membership includes medical doctors working for the Food and Drug Administration • Government-industry collaborative efforts • No accreditation system has been adopted • Educational syllabus compatible with the RCP model has been adopted • A certificate for “Certified Physician Investigator” through a qualifying examination is offered • Academic training and education: • Tufts Center for the Study of Drug Development (CSDD) • Harvard University School of Public Health
Harmonization of Pharmaceutical Medicine courses: The Council for Education in Pharmaceutical Medicine (CEPM) • Given the global and various professional aspects of pharmaceutical medicine, harmonization of the programs is necessary to ensure consistency of the programs at the global standard • The Council for Education in Pharmaceutical Medicine (CEPM), created in 2001 under the auspices of the IFAPP, is striving to harmonize the programs of the existing postgraduate courses in Pharmaceutical Medicine • The CEPM has already completed accreditation of Pharmaceutical Medicine courses in the UK (Cardiff and Surrey), Belgium, Barcelona and Stockholm
Need of Education and Training for clinical trial specialists and reviewers: What are the issues in Japan? • Several Biostatistics courses and Clinical Pharmacology programs are available in Japan • Various opportunities and methods exist to develop the expertise needed for effective drug development Programs and courses are rather isolated – efforts are therefore segmented • No clear criteria exists regarding the level of knowledge, skills and experience required for individuals to be accepted as experts in drug development and reviewers • The lack of clear criteria often results in inconsistencies in the quality of clinical trials conducted and the evaluation of associated clinical trial results
Vision for Pharmaceutical Medicine in Japan • Develop experts in drug development in industry, academia and regulatory agencies who are capable of leading high quality drug development with scientific regulatory process • As part of this mission, we wish to: • Promote excellence in Pharmaceutical Medicine in Japan • Set standards for Pharmaceutical Medicine • Certification • Develop programs and standards in collaboration with academia • Provide academic study guidance, Develop curriculum
Tokyo University Laboratory of Pharmaceutical Regulatory Science • Programs • Intensive Course (IC) • A seminar which concentrates on a specific timely topic. It will be conducted for two or three days and held twice a year • First IC was held on July 8 and 8, 2005 • Second IC is scheduled on January 25, 2006 • Seminar 1 was held on Aug.29, 2005 • First Mini Symposium was held on Sep. 22, 2005 • Regular Course (RC) • A seminar to educate specialists in statistics, data management techniques and evaluation of drug efficacy that are needed for the development and approval of new drugs • Lecture for the Graduate Students • Initiated at Oct 13, 2005
On-going Initiatives • Kitasato University School of Pharmaceutical Science • Post Graduate Pharmaceutical Medicine Course is planned to start in 2006 • International collaboration with Harvard University School of Public Health, FDA and other academic and regulatory bodies • Master and Doctoral degree will be awarded • Oita University Faculty of Medicine • Undergraduate lectures
Outline of Pharmaceutical Medicine Program proposed by JAPhMed • Scope of the Program • Accreditation system compatible with CEPM of IFAPP • Curriculum with practical case studies • Appraisal of the qualification by an external accredited body • Structured continuing education throughout a pharmaceutical physician’s career • Globally harmonized with IFAPP standard • Program Content • Pharmaceutical Medicine curriculum is comprised with following two parts • Basic Program • Principally covers the core curriculum of IFAPP syllabus in Pharmaceutical Medicine • Suitable for entry class investigators who will conduct clinical trials • Advanced Program • Workshop with case studies by the trainers with practical experiences
Internet / Independent Courses • 12 Sessions Certificate ILE Univ. Proposed Structure for Pharmaceutical Medicine in Japan • There are three ways to get qualification of Pharmaceutical Medicine professionals • Qualification of Pharmaceutical Medicine Professional will greatly improve employability Graduate Students + Company Employees + Physicians OJT, Conference, Symposium etc. Academia • Tokyo • Kitasato • Others • JAPhMed Course • Tokyo Univ. • Kitasato-Harvard Diploma Examination for Qualification executed by Independent Legal Entity (ILE) Qualified Pharmaceutical Medicine Professional (TBD)
14th International Conference on Pharmaceutical Medicine • ICPM2006 • 3-6 September, 2006, • Seoul, Korea • Beyond the Horizon • Beyond the Geographical Horizon • Beyond the Technical Horizon • Beyond the Functional Horizon • http://www.icpm2006.org
Conclusion • It is absolutely necessary to make all the efforts to consolidate training and education from isolated and segmented forms to a highly organized, continuous, and comprehensive activity in order to establish the highly qualified specialists of global standard for clinical trial and regulatory review
Acknowledgement • Prof. Masashi Takeuchi (Kitasato University, Dept. Pharmacy, Biostatistics) • Prof. Yuichi Sugiyama (Tokyo University, Dept. Pharmacy, Regulatory Science) • Dr. Kyoko Imamura (Janssen Pharmaceutical KK, Secretariat for Education task team, JAPhMed) • Dr. Akiyoshi Uchiyama (CEO of Artage, Chair for Education task team, JAPhMed) • Mr. Chris Albani (PRTM) • Mr. Yorozu Tabata (PRTM) • Ms. Mieko Hasegawa (Banyu/Merck)